Effects of renin–angiotensin–aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF: A meta-analysis of 13 randomized controlled trials;Auswirkungen der Inhibitoren des Renin-Angiotensin-Aldosteron-Systems auf Mortalität, Hospitalisation und diastolische Funktion bei Patienten mit HFpEF: Eine Metaanalyse von 13 randomisierten kontrollierten Studien

Herz

Volumn 41, Issue 1, 2016, Pages 76-86

  Zhang, Q ^a   Chen, Y ^a   Liu, Q ^a   Shan, Q ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin receptor; Angiotensin converting enzyme inhibitors; Antagonists; Heart failure with preserved ejection fraction; Mineralocorticoid receptor antagonists

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; IRBESARTAN; MINERALOCORTICOID ANTAGONIST; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; VALSARTAN; CARDIOTONIC AGENT;

6 MINUTE WALK DISTANCE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; DRUG EFFICACY; EXERCISE TEST; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HOSPITALIZATION; HUMAN; META ANALYSIS; PHYSICAL CAPACITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ADULT; AGED; COMORBIDITY; DRUG EFFECTS; EXERCISE TOLERANCE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; PREVENTION AND CONTROL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; COMORBIDITY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84958166859     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-015-4346-8     Document Type: Article

References (44)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. doi:10.1056/NEJMoa052256
2. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273(18):1450–1456
3. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–1675. doi:10.1056/NEJMoa010713
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341(10):709–717. doi:10.1056/NEJM199909023411001
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. doi:10.1056/NEJMoa1009492
6. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M (2000) Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Research 47(2):274–283
7. Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32(6):670–679. doi:10.1093/eurheartj/ehq426
8. Agarwal V, Briasoulis A, Messerli FH (2013) Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 18(4):429–437. doi:10.1007/s10741-012-9329-8
9. Fu M, Zhou J, Sun A, Zhang S, Zhang C, Zou Y, Fu M, Ge J (2012) Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction–a meta analysis of 7 prospective clinical studies. Int J Cardiol 155(1):33–38. doi:10.1016/j.ijcard.2011.01.081
10. Meune C, Wahbi K, Duboc D, Weber S (2011) Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther 16(3–4):368–375. doi:10.1177/1074248410391667
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
12. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. doi:10.1056/NEJMoa1313731
13. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction the Aldo-DHF randomized controlled trial. JAMA 309(8):781–791
14. Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 17(8):634–642. doi:10.1016/j.cardfail.2011.04.007
15. Kurrelmeyer KM, Ashton Y, Xu J, Nagueh SF, Torre-Amione G, Deswal A (2014) Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail. doi:10.1016/j.cardfail.2014.05.010
16. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110(5):558–565. doi:10.1161/01.cir.0000138680.89536.a9
17. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am College Cardiol 54(18):1674–1682. doi:10.1016/j.jacc.2009.08.021
18. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE (2008) The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94(5):573–580. doi:10.1136/hrt.2007.117978
19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467. doi:10.1056/NEJMoa0805450
20. Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD, MacDonald TM (2009) A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 11(10):980–989. doi:10.1093/eurjhf/hfp120
21. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2005) Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am College Cardiol 45(5):661–667. doi:10.1016/j.jacc.2004.11.038
22. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781. doi:10.1016/s0140-6736(03)14285-7
23. Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, Little WC (2010) Randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction. Circ Heart Fail 3(4):477–485
24. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345. doi:10.1093/eurheartj/ehl250
25. Zi M, Carmichael N, Lye M (2003) The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardi Drugs Ther 17(2):133–139
26. Song F, Gilbody S (1998) Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ 316(7129):471
27. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS, Investigators of the CES-C (2007) Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am College Card 49(6):687–694. doi:10.1016/j.jacc.2006.08.062
28. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology F, American Heart Association Task Force on Practice G (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American heart association task force on practice guidelines. J Am College Card 62(16):e147–e239. doi:10.1016/j.jacc.2013.05.019
29. Galderisi M (2005) Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 3:9. doi:10.1186/1476-7120-3-9
30. From AM, Borlaug BA (2011) Heart failure with preserved ejection fraction: pathophysiology and emerging therapies. Cardiovasc Ther 29(4):e6–21
31. Liu Y, Haddad T, Dwivedi G (2013) Heart failure with preserved ejection fraction: current understanding and emerging concepts. Curr Opin Cardiol 28(2):187–196. doi:10.1097/HCO.0b013e32835c5492
32. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S (2006) Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 48(1):80–86. doi:10.1161/01.HYP.0000224283.76347.8c
33. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C (2008) Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117(16):2051–2060. doi:10.1161/CIRCULATIONAHA.107.716886
34. Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107(5):714–720
35. Lee DS, Ghosh N, Floras JS, Newton GE, Austin PC, Wang X, Liu PP, Stukel TA, Tu JV (2009) Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail 2(6):616–623. doi:10.1161/circheartfailure.109.869743
36. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ (2000) Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 102(15):1788–1794
37. Dokainish H, Zoghbi WA, Lakkis NM, Al-Bakshy F, Dhir M, Quinones MA, Nagueh SF (2004) Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 109(20):2432–2439. doi:10.1161/01.cir.0000127882.58426.7a
38. Rivas-Gotz C, Manolios M, Thohan V, Nagueh SF (2003) Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol 91(6):780–784
39. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M, Tschope C (2007) Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116(6):637–647. doi:10.1161/circulationaha.106.661983
40. Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3(9):486–492. doi:10.1038/ncpneph0575
41. Weber KT (2001) Aldosterone in congestive heart failure. N Eng J Med 345(23):1689–1697. doi:10.1056/NEJMra000050
42. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD, Pilz S, Binder L, Stahrenberg R, Schmidt A, Marz W, Pieske B (2012) Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 33(2):203–212. doi:10.1093/eurheartj/ehr292
43. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102(22):2700–2706
44. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A (2001) Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am College Card 37(2):662–667